Biogen’s RoActemra Biosimilar Begins EU Approvals Process
The BIIB800 Candidate Is Only the Latest Of Biogen’s Deal-Driven Biosimilars
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.
You may also be interested in...
Biogen expects impending biosimilar launches to stimulate new growth, while unfavorable market conditions have taken their toll on the company.
Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.
Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.